PepGen Q1 net loss $18.0M, cash $175.2M; key clinical data expected mid-2024

PepGen Inc.

2024-Q1 EPS reported -$0.63

Cash and marketable securities $175.2M as of March 31, 2024, funding operations into 2026.
Net loss widened to $18.0M from $16.3M YoY; R&D expense $14.7M, G&A $5.1M.
Preliminary CONNECT1-EDO51 data (5 mg/kg dose) expected mid-2024; FDA orphan/rare pediatric designations granted.
FREEDOM1-DM1 preliminary data from at least 5 mg/kg cohort expected second half 2024.
Raised $86.3M net from February common stock offerings (ATM + underwritten).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

PepGen Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, PepGen Inc. announced its financial results for the quarter ended March 31, 2024 and other business updates.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.